This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
ClinicalTrials.gov record: NCT04361253
1. Trial at a Glance
ESCAPE was a randomized, double-masked, parallel phase 3 treatment trial evaluating high-titer COVID-19 convalescent plasma compared with standard plasma in patients with COVID-19 and infectious disease.
| Feature | ESCAPE |
|---|---|
| Condition | COVID; Infectious Disease |
| Phase | Phase 3 |
| Status | TERMINATED |
| Start date | 2020-04-30 |
| Primary completion date | 2021-04-01 |
| Lead sponsor | Brigham and Women's Hospital |
| Enrollment | 45 |
2. Clinical Question
The central clinical question was whether treatment with high-titer COVID-19 convalescent plasma produced different clinical outcomes compared with standard plasma among individuals with COVID-19.
Population
Individuals enrolled in the ESCAPE phase 3 trial with COVID-19.
Intervention
High-Titer COVID-19 Convalescent Plasma (HT-CCP), a biological intervention.
Comparator
Standard Plasma (FFP), a biological comparator intervention.
Primary question
Does the randomized comparison of HT-CCP versus standard plasma affect the modified WHO Ordinal Scale score at Day 14?
3. Trial Design
High-Titer COVID-19 Convalescent Plasma
Biological intervention containing high-titer COVID-19 convalescent plasma.
Standard Plasma
Biological comparator intervention using standard plasma (FFP).
4. Endpoints
| Endpoint | Time frame | Description |
|---|---|---|
| Modified WHO Ordinal Scale (MOS) score | Day 14 | The primary outcome is the MOS numerical score (score 0-9), where a score of 0 attributes to "no clinical evidence of infection" and a score of 9 attributes to "death". Eligibility requirements select individuals at level 3 or higher on the modified scale, but the Day 14 outcome can be any one of 10 levels. |
5. Planned Analysis
The registry identifies the Modified WHO Ordinal Scale (MOS) score at Day 14 as the primary endpoint. The ClinicalTrials.gov record does not report posted statistical analyses or outcome results.
For an ordinal clinical outcome such as the MOS score, analysis typically focuses on comparing the distribution of severity categories between randomized groups. Depending on the prespecified statistical analysis plan, approaches may include ordinal regression models or other methods designed for ordered categorical outcomes.
Higher score → greater clinical severity
An ordinal analysis uses the ordering of categories rather than treating the outcome as a simple binary event. The interpretation depends on the specific statistical model selected before analysis.
6. Statistical Methodology
Randomized treatment comparison
Randomization creates the framework for comparing outcomes between HT-CCP and standard plasma while reducing systematic differences between groups. The strength of the comparison depends on the enrolled population, adherence to assigned treatment, and the prespecified analysis approach.
Modified WHO Ordinal Scale analysis
The primary endpoint is an ordered clinical scale. Unlike continuous measurements such as laboratory values, ordinal outcomes represent categories with a meaningful ranking but not necessarily equal distances between categories.
Analysis population considerations
The registry describes a randomized phase 3 design but does not report analysis populations, missing-data handling procedures, or detailed statistical analysis plans.
7. Statistical Methods Explained
Why use an ordinal scale?
An ordinal scale can summarize multiple levels of clinical severity in one outcome. It preserves information about improvement or worsening across ordered categories.
What does a Day 14 MOS score represent?
The Day 14 MOS score represents the patient's clinical status at that assessment time using the modified WHO Ordinal Scale from 0 to 9.
Why is an ordinal endpoint different from mortality alone?
Mortality captures only one extreme outcome. An ordinal scale can incorporate several levels of clinical status, allowing analysis of the full range of observed severity categories.
Why does masking matter statistically?
Double masking can reduce the influence of expectations on treatment administration, assessment, and reporting of outcomes.
Why is the sample size important?
The enrollment of 45 participants affects the precision of statistical estimates. Smaller randomized trials generally produce greater uncertainty around treatment comparisons.
8. Limitations
- No posted results: ClinicalTrials.gov does not report statistical analyses or outcome estimates for the primary endpoint.
- Sample size: The trial enrolled 45 participants, which affects the precision of estimated treatment differences.
- Ordinal endpoint interpretation: The meaning of any treatment comparison depends on the statistical model and assumptions used for the ordered outcome.
- Registry detail: The available record does not report subgroup analyses, missing-data methods, interim analyses, multiplicity procedures, or detailed analysis populations.
- Terminated status: The registry lists the trial status as terminated.
9. Why This Trial Matters Statistically
ESCAPE illustrates several important concepts in clinical trial statistics: randomized comparisons, masked treatment assignment, biological interventions, and analysis of ordered clinical outcomes.
| Concept | How it appears in ESCAPE |
|---|---|
| Randomization | Randomized allocation to two biological interventions |
| Masking | Double-masked trial design |
| Parallel design | Two-arm parallel assignment |
| Ordinal outcomes | Modified WHO Ordinal Scale score from 0-9 |
| Time-point assessment | Primary endpoint measured at Day 14 |
| Clinical severity measurement | Ordered categories ranging from no clinical evidence of infection to death |
10. Sources
- ClinicalTrials.gov: NCT04361253.
Continue through the Clinical Biostats knowledge graph
Explore clinical trial methods, statistical concepts, and analysis workflows through additional Clinical Biostats resources.
11. Record Summary
ESCAPE was a phase 3 randomized, double-masked, parallel treatment trial evaluating high-titer COVID-19 convalescent plasma versus standard plasma. The registry identifies the Modified WHO Ordinal Scale score at Day 14 as the primary endpoint. The ClinicalTrials.gov record reports trial design characteristics but does not provide posted statistical analyses or outcome results.